Safety and Efficacy of BI 1015550, a Preferential Inhibitor of Phosphodiesterase 4B, in Patients with Idiopathic Pulmonary Fibrosis: a Phase 2 Trial* 

¹ Uniklinikum Dresden; Universitätsklinikum Carl Gustav Carus Dresden; Pneumologie

² Unità Operativa Complessa DI Pneumologia, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica del Sacro Cuore, Rome, Italy

³ Nippon Medical School, Tokyo, Japan

⁴ Hôpital Louis Pradel, Centre Coordonnateur National de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France

⁵ Translational Medicine+Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. Kg, Biberach, Germany

⁶ Ta Inflammation Med, Boehringer Ingelheim International, Ingelheim am Rhein, Germany

⁷ Ild Unit, Pulmonology Department, Hospital Universitario de la Princesa, University Autonoma de Madrid, Madrid, Spain

⁸ Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

⁹ Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, Ct, USA

¹⁰ Boehringer Ingelheim Pharma GmbH & Co. Kg, Ingelheim am Rhein, Germany

¹¹ Keck Medicine of Usc, Los Angeles, Ca, United States